Published in Health Business Week, October 13th, 2006
The proceeds will enable continued development of the company's proprietary technology platforms, including the recently announced ACTC technique to generate human embryonic stem cell while preserving the donor embryo's potential for continued development. Included in ACTC's priorities for use of proceeds are the three therapeutic programs currently targeted by ACTC for advancement into the human clinical trial phase. These priorities include therapies for treatment of degenerative eye disease, heart and vascular disease, and technology to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.